News | October 01, 2010

Bioresorbable Stent Company Raises $8.5 Million

October 1, 2010 – The maker of a biodegradable stent has brought in $8.5 million during a new round of venture financing from existing investors. Arterial Remodeling Technologies (ART) now has $17 million in total investment from Matignon Technologies, Amundi Private Equity Funds and InnoBio Fund managed by CDC Enterprises.

"ART has made very significant progress over the past 22 months, and this new cash infusion will accelerate the development of our breakthrough approach of simultaneously balancing biocompatibility, biomechanics, and bioresorption within a bioresorbable PLA (polylactic acid) stent," said Machiel van der Leest, CEO.

In May 2010, ART disclosed the results of an in vivo study of 48 porcine arteries implanted with its biodegradable stent. The study demonstrated that the stent’s biodegradation is measurable and begins at the first day of implant, and it retains high radial strength, thus maintaining its structural integrity during biodegradation. Additionally, the stent causes virtually no inflammation.

"Our disruptive technology for fully resorbable coronary stents is designed to promote natural remodeling of an injured artery after angioplasty,” van der Leest said.

Earlier this year, validating data regarding ART's bioresorbable stent was published in the January 2010 special supplement of EuroIntervention, a peer-reviewed journal. The paper was authored by Antoine Lafont, M.D., Ph.D., head of Interventional Cardiology Department, Georges Pompidou Hospital (Paris), past chairman, Interventional Cardiology Group, European Society of Cardiology (ESC).

ART's bioresorbable stent is designed to be delivered by conventional stenting techniques, is balloon-expandable and meets the market standard of 6-French compatibility. ART's biopolymers have been developed in conjunction with one of the world's leading authorities in polymer chemistry, Professor Michel Vert, who is former director of the Research Center for Artificial Biopolymers at France's National Center for Scientific Research (Centre National de Recherche Scientifique/CNRS).

For more information: www.art-stent.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init